Back to search

Mycobacterial r32-kDa Ag specific T cell responses correlate with successful treatment and heightened antimicrobial response in human leprosy patients.


BACKGROUND: Immunological characterization of mycobacterial peptides may help not only in the preparation of a vaccine for leprosy but also in developing in vitro T cell assay that could perhaps be used as an in vitro correlate for treatment outcome. The main goal of this study was to evaluate the use of r32-kDa Ag stimulated T cell assay as a surrogate marker for treatment outcome and monitor Vitamin D Receptor (VDR) mediated antimicrobial responses during MDT in leprosy.

METHODS: Newly diagnosed tuberculoid & lepromatous leprosy patients were enrolled and followed-up during their course of multi-drug-therapy at 6(th) and 12(th) month. IFN-γ, IL-10, IL-17 and IL-23 levels in culture supernatants and expression of VDR, TLR2, LL37 & DEFB in r32kDa-stimulated PBMC were performed. Controls comprised of house-hold contacts and healthy endemic subjects.

RESULTS: Significant differences were observed in the levels of IFN-γ, IL-17, IL-23, VDR and antimicrobial-peptides LL37 & DEFB after treatment and when compared to that of HHC and HC respectively.

CONCLUSIONS: These findings suggest that responses to r32-kDa Ag reflect an improved immunological and antimicrobial response in leprosy patients during therapy, thereby indicating its potential use as an immune correlate in the treatment of leprosy patients.

More information

Journal Article
Neela VSK
Devalraju KP
Pydi SS
Sunder SR
Adiraju KR
Singh SS
Mpjs A
Valluri V